The antiviral response to Tenofovir disoproxil fumarate (TDF) is comparable in Lamivudine (LAM)-naïve and LAM-experienced subjects treated for chronic Hepatitis B (CHB)
M Manns, T Berg, P Buggisch, S Mauss, G Teuber, WO Böcher, J Sorbel, J Anderson, E Mondou, F Rousseau · Zeitschrift für Gastroenterologie · 2008 · Heft 09
Bibliografische Angaben
Zusammenfassung
Aims: TDF, an obligate chain terminator and a nucleotide analogue, approved for the treatment of HIV-1 also has activity against hepatitis B virus (HBV). Treatment response for a subset of subjects from Studies 102 and 103 previously treated with LAM) was compared to subjects naïve to LAM in these two pivotal studies. Methods: These double-blind studies randomized mono-infected subjects with HBeAg positive (+) or HBeAg negative (-) chronic hepatitis B (CHB) in a 2:1 ratio to TDF or ADV. Entry criteria included 18–69 years of age, compensated liver disease, a Knodell necroinflammatory score≥3, ALT >2xULN (HBeAg+)…
